Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 101

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 101
---
 the development of our product candidates
could be delayed or otherwise adversely affected.

Even though we believe we carry commercially reasonable
business interruption and liability insurance, we might suffer losses as a result of business interruptions that exceed the coverage available
under our insurance policies or for which we do not have coverage. For example, we are not insured against terrorist attacks or cyberattacks.
Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover,
any such event could delay the development of our product candidates.

Sales of a significant number of our Common Shares in the public
markets or significant short sales of our Common Shares, or the perception that such sales could occur, could depress the market price
of our Common Shares and impair our ability to raise capital.

Sales of a substantial number of our Common Shares
or other equity-related securities in the public markets, could depress the market price of our Common Shares. If there are significant
short sales of our Common Shares, the price decline that could result from this activity may cause the share price to decline more so,
which, in turn, may cause long holders of the Common Shares to sell their shares, thereby contributing to sales of Common Shares in the
market. Such sales also may impair our ability to raise capital through the sale of additional equity securities in the future at a time
and price that our management deems acceptable, if at all.

If securities or industry analysts do not publish or cease publishing
research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports
regarding our business or the Common Shares, our share price and trading volume could decline.

The trading market for the Common Shares will be
influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors.
We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or provide favorable coverage.
If any of the analysts who may cover us adversely change their recommendation regarding the Common Shares, or provide more favorable relative
recommendations about our competitors, the price of our Common Shares would likely decline. If any analyst who may cover us were to cease
coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could
cause the price of our Common Shares or trading volume to decline.

ITEM 4. INFORMATION ON THE COMPANY